DOCSLIB.ORG

Beyond PSA Testing for Prostate Cancer

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Beyond PSA Testing for Prostate Cancer Perspective Beyond PSA testing for prostate cancer Better biomarkers are needed to ensure early and accurate detection and prognosis of prostate cancer rostate cancer is now the most common cancer for patients with a Gleason score between 6 and 10 or diagnosed in men in Australia,1 and Australia has accurate prognosis. P one of the highest incidence rates of prostate There are two main clinical pathology objectives that need cancer in the world, with an estimated age-standardised to be met by biomarker technology. rate of 119.2 per 100 000 men.2 Before 1960, the primary diagnostic test for prostate cancer was the prostatic acid Early, accurate detection of the cancer: PSA testing phosphatase test. This was eventually replaced in the fails to achieve this because of the large number of fi 1980s by the prostate-speci c antigen (PSA) test. false positives. A PSA reading > 4 ng/mL has a PSA, a glycoprotein enzyme encoded in humans by the positive predictive value of 30%, meaning that less KLK3 gene, was discovered by Flocks and colleagues in than one-third will have prostate cancer, and 3 if 4 ng/mL, a negative predictive value of 85%, 1960. Although a few small studies in the early 1980s 9,10 suggested that PSA might be useful in the diagnosis of meaning that 15% will have prostate cancer. Both prostate cancer,4 other studies found that its primary of these problems result in poor patient management benefit was for monitoring cancer progression and the and less than optimal outcomes. impact of treatment.5 As a result, in 1986 the United States Early, accurate prognosis: although PSA testing has Food and Drug Administration (FDA) approved PSA been used to help predict disease progression, its testing for monitoring the progression of prostate cancer. lack of expression in many aggressive cancers leads However, in 1994, despite scant evidence for its accuracy to problems with reliability for early, accurate as a diagnostic test, the FDA succumbed to pressure from prognosis. biotechnology companies, clinicians and men’s lobby groups and approved the PSA test for screening; but only Clearly, PSA is not an optimal biomarker for accurate when combined with a digital rectal examination and prostate cancer diagnosis and prognosis, but it is the in men aged 50 years and older.6 current standard that clinicians are generally expected to use. Problems with PSA testing Clear identification of the core of the tumour is ideal, including its leading edges and invasive fronts, to The standard PSA total blood test has a sensitivity range achieve an accurate Gleason grade and prognosis. of 78e100%, with a specificity range of 6e66%.7 However, PSA immunochemistry does not currently Sensitivity may be improved by combining total PSA with enable reproducible, if any, visualisation of the cancer other isoforms; however, at the expense of specificity.8 in some tissue biopsies or prostatectomy samples. It Notably, in an attempt to avoid biopsy, measuring the therefore adds minimally to Gleason grading. The free PSA percentage for patients with total PSA levels in lack of effective biomarkers for visualising prostate the grey area of 4e10 ng/mL, although more accurate cancer and the reliance on standard haematoxylin than total PSA alone, still results in missed cancers. and eosin stains contributes to unreliable Gleason grading. Unfortunately, elevated serum PSA concentrations are not specific to prostate cancer, being also associated with PSA screening: evidence and controversies benign prostatic hyperplasia, prostatitis, other inflammatory conditions, recent sexual intercourse and Two large randomised studies designed to determine the even bicycle riding. Indeed, less than 50% of men who benefit of PSA screening yielded apparently conflicting have undergone a biopsy in response to a PSA reading results. In the US, the Prostate, Lung, Colorectal and > 4.0 ng/mL are diagnosed with prostate cancer.9 1 Ovarian Cancer Screening Trial, which randomised Doug Brooks Further, about 15% of men with a “negative” PSA reading 76 693 men aged 55e74 years between PSA screening 1 have prostate cancer. Ian N Olver with digital rectal examination and usual care, showed Adrian J Thus, PSA testing does not effectively meet any of the that up to 15 years median follow-up, the rate of death Esterman1,2 major requirements for pathological assessment, and PSA from prostate cancer was very low and did not differ is only useful as a biomarker for detection, prognosis and significantly between the two study groups.11 The 1 University of South 4 June 2018 Australia Cancer monitoring in patients who have cancers that secrete it in European Randomized Study of Screening for Prostate j Research Institute, high concentrations. The biology of PSA, including its Cancer randomised 182 160 men aged 50e74 years to PSA Adelaide, SA. fl 2 Australian Institute secretion during in ammatory reactions and its control of screening compared with a control group who were not of Tropical Health the fluidity of ejaculate, limits its use in defining prostate screened. The study showed a mortality advantage at 13 and Medicine, James e Cook University, cancer pathology. Moreover, PSA immunohistochemistry years of 21% in the 162 243 participants aged 55 69 12 MJA 208 (10) Cairns, QLD. does not provide a reliable system for detecting and years. However, a recent combined analysis of the two Doug.Brooks@ visualising prostate cancer in biopsy samples. These trials concluded that after accounting for differences in unisa.edu.au limitations result in missed cancer diagnoses, unnecessary implementation and settings, the trials provide 426 biopsies on patients, over-treatment with surgery, and compatible evidence that screening reduces prostate 13 doi: 10.5694/mja18.00324 inaccurate information on which to base a clinical decision cancer mortality. Perspective Notably, a mortality benefit takes many years to become However, these approaches do not distinguish primary apparent, but the harms in a large group subject to pathology from secondary downstream biology; over-diagnosis and subsequent over-treatment can affect consequently, they rely on associations to provide an quality of life immediately. The two most prominent indicator of outcome. This has been a major limitation, as harms resulting from treatment for prostate cancer are investigators use their test cohorts to develop a set of impotence and incontinence. This is why the Australian biomarkers or an algorithm. The problem with this Government Standing Committee on Screening has approach is that secondary cohort testing often fails, as recommended against population-based PSA screening, the biomarker panel is specific to certain patients or and has suggested that better tests are needed.14 sample groups. We believe that prostate cancer biomarker development The search for alternative biomarkers should first recognise the critical cell biology and only then use the technology to develop the biomarkers, and A biomarker is any biological molecule found in blood, finally, test the biomarkers on independent highly other body fluids or tissues that can be objectively annotated cohorts of patient samples with accurate measured and evaluated as a sign of a normal or abnormal longitudinal information. The recent identification of biological process and a pathogenic condition or altered endosome biology in prostate cancer is a step disease. Unfortunately, this broad definition has towards such an alternative approach.19 Interestingly, contributed to many of the problems in biomarker PSA and many of the other biomarkers under current research, with attempts to fit biomarkers to a purpose investigation have direct biology associated with this rather than recognising that each biomarker has a place in pathway and, for example, like PSA, are secreted from the pathological process. Once we fully understand the endosomal organelles. Endosome control secretion is a biology of the disease, it should be easier to assign a logical first choice for biomarker investigation to identify biomarker to a particular functional role. This might then a candidate biomarker that is consistently secreted from meet the need for diagnosis, prognosis, predictive cancer cells and reliably detected in circulation. We are at biomarkers and surrogate biomarkers, instead of pushing a point where biomarker discovery needs to be linked PSA into different categories and trying to adapt it for to critical cancer cell biology, so that we can identify multiple purposes. We believe we are at the point of biomarkers that reflect the primary pathology, provide needing to return to the cell biology of the disease and optimal detection, enable visualisation of the develop biomarkers that accurately reflect different pathogenesis in biopsies, and facilitate early, accurate aspects of the pathogenesis. A recently commissioned prognosis. report provides a detailed review of the appropriate use 15 and implementation of cancer biomarkers. Conclusion In the search for new prostate cancer biomarkers, a number of technologies and approaches have been Current PSA-based diagnostic tests cannot accurately detect prostate cancer. After the cancer has been employed. These include proteomics, secretomics, fi lipidomics, metabolomics, detailed analysis of the cell identi ed, the histopathological grading is less than biology of the cancer, and systems biology. New reliable; and current pathology tests are not able to technologies together with the evaluation of combinations effectively distinguish between indolent and aggressive
Load more

Recommended publications
  • Secretome Identification of Immune Cell Factors Mediating Metastatic Cell Homing Received: 07 September 2015 1,2 3 4 5 6 Accepted: 02 November 2015 Brian A
    www.nature.com/scientificreports OPEN Secretome identification of immune cell factors mediating metastatic cell homing Received: 07 September 2015 1,2 3 4 5 6 Accepted: 02 November 2015 Brian A. Aguado , Jia J. Wu , Samira M. Azarin , Dhaval Nanavati , Shreyas S. Rao , 7 8 7,9,10 Published: 04 December 2015 Grace G. Bushnell , Chaitanya B. Medicherla & Lonnie D. Shea Metastatic cell homing is a complex process mediated in part by diffusible factors secreted from immune cells found at a pre-metastatic niche. We report on connecting secretomics and TRanscriptional Activity CEll aRray (TRACER) data to identify functional paracrine interactions between immune cells and metastatic cells as novel mediators of homing. Metastatic breast cancer mouse models were used to generate a diseased splenocyte conditioned media (D-SCM) containing immune cell secreted factors. MDA-MB-231 metastatic cell activity including cell invasion, migration, transendothelial migration, and proliferation were increased in D-SCM relative to control media. Our D-SCM secretome analysis yielded 144 secreted factor candidates that contribute to increased metastatic cell activity. The functional mediators of homing were identified using MetaCore software to determine interactions between the immune cell secretome and the TRACER-identified active transcription factors within metastatic cells. Among the 5 candidate homing factors identified, haptoglobin was selected and validated in vitro and in vivo as a key mediator of homing. Our studies demonstrate a novel systems biology approach to identify functional signaling factors associated with a cellular phenotype, which provides an enabling tool that complements large-scale protein identification provided by proteomics. During cancer progression, the likelihood of patient survival significantly declines with the formation of metastatic tumors.
    [Show full text]
  • HCSD: the Human Cancer Secretome Database
    Downloaded from orbit.dtu.dk on: Sep 25, 2021 HCSD: the human cancer secretome database Feizi, Amir; Banaei-Esfahani, Amir; Nielsen, Jens Published in: Database: The Journal of Biological Databases and Curation Link to article, DOI: 10.1093/database/bav051 Publication date: 2015 Document Version Publisher's PDF, also known as Version of record Link back to DTU Orbit Citation (APA): Feizi, A., Banaei-Esfahani, A., & Nielsen, J. (2015). HCSD: the human cancer secretome database. Database: The Journal of Biological Databases and Curation, 2015, [bav051]. https://doi.org/10.1093/database/bav051 General rights Copyright and moral rights for the publications made accessible in the public portal are retained by the authors and/or other copyright owners and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights. Users may download and print one copy of any publication from the public portal for the purpose of private study or research. You may not further distribute the material or use it for any profit-making activity or commercial gain You may freely distribute the URL identifying the publication in the public portal If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately and investigate your claim. Database, 2015, 1–8 doi: 10.1093/database/bav051 Database tool Database tool HCSD: the human cancer secretome database Amir Feizi1,2,AmirBanaei-Esfahani1 and Jens Nielsen1,2,3,* 1Novo Nordisk Foundation Center for Biosustainability, Department of Biology and Biological Engineering, Chalmers University of Technology, SE-41296 Go¨teborg, Sweden, 2Novo Nordisk Foundation Center for Biosustainability, Technical University of Denmark, Fremtidsvej 3, DK-2970 Downloaded from Hørsholm, Denmark and 3Novozymes A/S, Krogshoejvej 36, 2880 Bagsvaerd, Denmark *Corresponding author: Tel: þ46 31 772 3854; Fax: þ46 31 772 3801; Email: [email protected] Citation details: Feizi,A., Banaei-Esfahani,A.
    [Show full text]
  • The Embryo-Endometrium Crosstalk During Human Implantation
    ADVERTIMENT. Lʼaccés als continguts dʼaquesta tesi queda condicionat a lʼacceptació de les condicions dʼús establertes per la següent llicència Creative Commons: http://cat.creativecommons.org/?page_id=184 ADVERTENCIA. El acceso a los contenidos de esta tesis queda condicionado a la aceptación de las condiciones de uso establecidas por la siguiente licencia Creative Commons: http://es.creativecommons.org/blog/licencias/ WARNING. The access to the contents of this doctoral thesis it is limited to the acceptance of the use conditions set by the following Creative Commons license: https://creativecommons.org/licenses/?lang=en The embryo-endometrium crosstalk during human implantation: a focus on molecular determinants and microbial environment Paula Vergaro Varela Thesis for Doctoral Degree in Cell Biology by Universitat Autònoma de Barcelona, Department of Cell Biology, Physiology and Immunology Barcelona, 2019 Supervisors: Dr. Rita Vassena and Prof. Josep Santaló Pedro All published papers were reproduced with permission from the publishers. Cover picture from iStock by Getty Images (iStockphoto LP.) A meus pais e a miña irmá, SUMMARY Implantation failure is a major cause of human infertility and currently the most limiting step in Assisted Reproductive Technologies (ART). It can be caused by both maternal and embryonic factors, as well as by defective crosstalk between them. Due to technical and ethical limitations, it is not possible to study human implantation in vivo. The knowledge about implantation has been mainly obtained from animal models which fail to represent the physiology of the human process. Additionally, a number of in vitro studies have investigated the molecular mechanisms underlying implantation, mostly focussing on either the embryo or the endometrium in a unilateral manner.
    [Show full text]
  • Desmin Expression in Colorectal Cancer Stroma Correlates with Advanced Stage Disease and Marks Angiogenic Microvessels
    Arentz et al. Clinical Proteomics 2011, 8:16 http://www.clinicalproteomicsjournal.com/content/8/1/16 CLINICAL PROTEOMICS RESEARCH Open Access Desmin expression in colorectal cancer stroma correlates with advanced stage disease and marks angiogenic microvessels Georgia Arentz1,2, Tim Chataway3, Timothy J Price1,4, Zaipul Izwan1,2, Gemma Hardi1,2, Adrian G Cummins4,5 and Jennifer E Hardingham1,2* * Correspondence: jenny. Abstract [email protected] 1 Department of Haematology- Introduction: Biomarkers that improve stratification of colorectal cancer patients for Oncology, The Queen Elizabeth Hospital, Woodville, SA 5011, adjuvant therapy versus resection alone, or that are predictive of response to Australia therapeutic agents, have the potential to greatly improve patient selection for such Full list of author information is therapies. The aim was to determine proteins differentially expressed within the available at the end of the article malignant epithelial glands and closely associated stromal elements compared to matched normal mucosa, and to characterise the over-expression of one such protein as a potential biomarker. Methods: Protein from laser microdissected tumor and normal mucosa was analysed by two dimensional difference gel electrophoresis (2D DIGE) and mass spectrometry to determine differentially over expressed tumor proteins. Tumor over-expression of one such protein, desmin, was quantified using immunofluorescence staining in a larger cohort. Dual staining for desmin and vimentin, or desmin and von Willebrand factor, was performed to determine the cell type of interest. Results: Desmin expression was significantly increased between stage I and III tumors, (P < 0.0001), and stage II and III tumors, (P < 0.0001). Strong focal desmin expression was found in stroma directly adjacent to carcinomatous glands and microvessels.
    [Show full text]
  • Original Article Metabolomic Profiling of Human Follicular Fluid from Patients with Repeated Failure of in Vitro Fertilization
    Int J Clin Exp Pathol 2014;7(10):7220-7229 www.ijcep.com /ISSN:1936-2625/IJCEP0001500 Original Article Metabolomic profiling of human follicular fluid from patients with repeated failure of in vitro fertilization using gas chromatography/mass spectrometry Lan Xia, Xiaoming Zhao, Yun Sun, Yan Hong, Yuping Gao, Shuanggang Hu Shanghai Key Laboratory for Assisted Reproduction and Reproductive Genetics, Center for Reprodutive Medcine, Renji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, China Received July 22, 2014; Accepted August 23, 2014; Epub September 15, 2014; Published October 1, 2014 Abstract: Objective: To establish a gas chromatography/mass spectrometry (GC/MS)-based metabolomics method to compare the metabolites in the follicular fluid (FF) from patients with in vitro fertilization (IVF) and repeated IVF failure (RIF). Methods: A prospective study was employed in Center for Reprodutive Medcine, Renji Hospital, Shanghai, China, between January and October 2010. FF samples were collected from 13 patients with RIF and 15 patients who achieved pregnancy after the first IVF cycle. Results: Partial least squares (PLS) discriminant analysis of the PCA data revealed that the samples were scattered into two different regions. FF from the two groups differed with respect to 20 metabolites. FF from RIF group showed elevated levels of several amino acids (valine, threonine, isoleucine, cysteine, serine, proline, alanine, phenylalanine, lysine, methionine and ornithine), and reduced levels of dicarboxylic acids, cholesterol and some organic acids. Conclusions: The studies corroborated successful determi- nation of the levels of metabolite in the FF. Keywords: In vitro fertilization (IVF), follicular fluid, repeated IVF failure (RIF), metabolomics Introduction or suboptimal embryo culture conditions), endo- metriosis, hydrosalpinges or suboptimal ovari- Despite the advancements in infertility man- an stimulation [3, 4].
    [Show full text]
  • The Actors of Human Implantation: Gametes, Embryo, Endometrium
    5 The Actors of Human Implantation: Gametes, Embryo, Endometrium Virginie Gridelet et al.* University of Liège (ULg) Belgium 1. Introduction The success of pregnancy depends on a receptive endometrium, a normal blastocyst, a synchronized cross-talk at the maternal–fetal interface at the time of implantation, and finally a successful placentation and remodeling of uterine vasculature. In routine, less than 5% of oocytes collected in in vitro fertilization (IVF) cycles and only 20 to 25% of embryos transferred lead to a birth. Implantation and placentation processes remain the black box of fertility, involving following steps: fertilization, endometrial receptivity, embryo implantation (apposition-adhesion-invasion), trophoblastic differentiation and invasion (Cartwright et al., 2010). At the time of fertilization, a cascade of cytokines mediates the oocyte-sperm dialogue long time before embryo implantation in the endometrium. At the oocyte side, genomic and proteomic profiles of good follicle are under investigation. Markers of oocytes with high subsequent embryo implantation potential are one of the main goals of the actual research. For example, granulocyte colony stimulating factor (G-CSF or CSF-3) in individual follicular fluids (FF) appears to correlate with the birth potential of the corresponding embryo in two opposite models of ovarian monitoring, standard ovarian hyperstimulation and modified natural IVF/ICSI cycles (Ledee et al., 2008b; Ledee et al., 2011a). To achieve the fertilization step, a good quality oocyte must meet a normal sperm with low DNA damages, leading to the development of a functionally normal blastocyst able to dialogue with maternal endometrium. Sperm DNA damages include fragmentation, trouble of condensation and epigenetic modification that could impair implantation process and methylation of imprinted genes (Boitrelle et al., 2011; Tavalaee et al., 2009).
    [Show full text]
  • Novel Tools for Prostate Cancer Prognosis, Diagnosis, and Follow-Up
    Hindawi Publishing Corporation BioMed Research International Volume 2014, Article ID 890697, 9 pages http://dx.doi.org/10.1155/2014/890697 Review Article Novel Tools for Prostate Cancer Prognosis, Diagnosis, and Follow-Up Andreas Dimakakos, Athanasios Armakolas, and Michael Koutsilieris Physiology Laboratory, Medical School, National and Kapodistrian University of Athens, Mikras Asias 75, 11527 Athens, Greece Correspondence should be addressed to Michael Koutsilieris; [email protected] Received 7 February 2014; Accepted 9 April 2014; Published 4 May 2014 Academic Editor: Giovanni Luca Gravina Copyright © 2014 Andreas Dimakakos et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. Prostate-specific antigen (PSA) is the main diagnostic tool whent i comes to prostate cancer but it possesses serious limitations. Therefore, there is an urgent need for more sensitive and specific biomarkers for prostate cancer prognosis and patient follow- up. Recent advances led to the discovery of many novel diagnostic/prognostic techniques and provided us with many worthwhile candidates. This paper briefly reviews the most promising biomarkers with respect to their implementation in screening, early detection, diagnostic confirmation, prognosis, and prediction of therapeutic response or monitoring disease and recurrence; and their use as possible therapeutic targets. This review also examines the possible future directions in the field of prostate cancer marker research. 1. Introduction Studies have shown that the levels of free PSA in the serum act as a more accurate marker for BPH, while the levels of Prostate cancer is the sixth leading cause of cancer-related 1-antichymotrypsin-PSA complex more accurately predict death in men (it is now the second in the United States prostate cancer [5].
    [Show full text]
  • Comparative Secretome Profiling and Mutant Protein Identification in Metastatic Prostate Cancer Cells by Quantitative Mass Spect
    CANCER GENOMICS & PROTEOMICS 15 : 279-290 (2018) doi:10.21873/cgp.20086 Comparative Secretome Profiling and Mutant Protein Identification in Metastatic Prostate Cancer Cells by Quantitative Mass Spectrometry-based Proteomics OH KWANG KWON, JU MI JEON, EUNJI SUNG, ANN-YEA NA, SUN JOO KIM and SANGKYU LEE College of Pharmacy, Research Institute of Pharmaceutical Sciences, BK21 Plus KNU Multi-Omics-based Creative Drug Research Team, Kyungpook National University, Daegu, Republic of Korea Abstract. Background: Secreted proteins play an important Twenty-five percent of patients progress from initial role in promoting cancer (PCa) cell migration and invasion. hormone sensitivity to castrate-resistant prostate cancer Proteogenomics helps elucidate the mechanism of diseases, (CRPC), that no longer accepts hormone therapy (2). discover therapeutic targets, and generate biomarkers for Consequently, metastatic castration-resistant prostate cancer diagnosis through protein variations. Materials and (mCRPC) is considered incurable; many of these patients Methods: We carried out a mass spectrometry-based develop recurrence with a poor outlook, eventually leading proteomic analysis of the conditioned media (CM) from two to death. Metastasis of cancer is a multi-step cascade that human prostate cancer cell lines, belonging to different includes local migration, invasion, and colonization. PCa is metastatic sites, to identify potential metastatic and/or able to metastasize to liver, lung, and brain, but almost aggressive factors. Results: We identified a total of 598 proprietarily associates with a high incidence of bone proteins, among which 561 were quantified based on metastases (3). Despite many studies on mCRPC, the proteomic analysis. Among the quantified proteins, 128 were metastatic mechanism and/or involved factors are still not up-regulated and 83 were down-regulated in DU145/PC3 clear.
    [Show full text]
  • Recent Advances in in Vitro Fertilization: Proteomics, Secretomics, Metabolomics and in Vitro Maturation
    REVIEW (Derleme) RECENT ADVANCES IN IN VITRO FERTILIZATION: PROTEOMICS, SECRETOMICS, METABOLOMICS AND IN VITRO MATURATION Ercan BASTU, Gulsah KESKIN, Hasan SERDAROGLU Department of Obstetrics and Gynecology, Istanbul University, Faculty of Medicine, Istanbul, Turkey SUMMARY Since its first successful result in 1978, clinicians and researchers have been working on increasing the efficiency and safety of in vitro fertilization (IVF). As a result of advances in technology and understanding of human reproduction, IVF success rates have increased while high-order multiple pregnancy (triplets and more) rates have decreased. On the other, there is opportunity for further improvement as many couples still face 'unexplained infertility' and high rates of twin pregnancies. Latest technologic and scientific improvements in IVF are promising. The aim of this review is to present the latest advances in the fields of proteomics, secretomics, metabolomics and oocyte culture, how they can potentially improve embryo selection and in vitro maturation (IVM) and subsequently their possible impact on the safety and efficacy of IVF. Key words: in vitro fertilization, in vitro maturation, metabolomics, proteomics, secretomics Journal of Turkish Society of Obstetrics and Gynecology, (J Turk Soc Obstet Gynecol), 2013; Vol: 10, Issue: 1, Pages: 1- 8 IN V‹TRO FERT‹L‹ZASYON’DA GÜNCEL YAKLAfiIMLAR: PROTEOM‹KLER, SEKRETOM‹KLER, METABOLOM‹KLER VE IN V‹RO MATURASYON ÖZET 1978'de insanlarda yap›lm›fl olan ilk baflar›l› in vitro fertilizasyon (IVF) uygulamas›ndan beri, IVF'nin etkinli¤ini ve güvenli¤ini gelifltirme çabalar› uzmanlar taraf›ndan sürdürülmektedir. Teknolojideki geliflmeler ve insan üremesi hakk›nda artan bilgiler ›fl›¤›nda, IVF baflar› oranlar› artarken, çoklu gebelik (üçüz, dördüz ve üstü) oranlar› düflmüfltür.
    [Show full text]
  • Bone Morphogenetic Protein Antagonist Gremlin-1 Regulates Colon Cancer Progression
    Biol. Chem. 2014; x(x): xxx–xxx George S. Karagiannis , Natasha Musrap , Punit Saraon , Ann Treacy , David F. Schaeffer , Richard Kirsch , Robert H. Riddell and Eleftherios P. Diamandis* Bone morphogenetic protein antagonist gremlin-1 regulates colon cancer progression Abstract: Bone morphogenetic proteins (BMP) are phylo- E-cadherin-upregulation of N-cadherin) and overexpres- genetically conserved signaling molecules of the trans- sion of Snail. Collectively, our data support that GREM1 forming growth factor-beta (TGF-beta) superfamily of promotes the loss of cancer cell differentiation at the can- proteins, involved in developmental and (patho)physi- cer invasion front, a mechanism that may facilitate tumor ological processes, including cancer. BMP signaling has progression. been regarded as tumor-suppressive in colorectal cancer (CRC) by reducing cancer cell proliferation and invasion, Keywords: angiogenesis; bone morphogenetic protein; and by impairing epithelial-to-mesenchymal transition cancer-associated fibroblasts; colorectal cancer; epithe- (EMT). Here, we mined existing proteomic repositories lial-to-mesenchymal transition; gremlin-1; stroma; tumor to explore the expression of BMPs in CRC. We found that microenvironment. the BMP antagonist gremlin-1 (GREM1) is secreted from heterotypic tumor-host cell interactions. We then sought DOI 10.1515/hsz-2014-0221 to investigate whether GREM1 is contextually and mecha- Received June 26 , 2014 ; accepted August 1 , 2014 nistically associated with EMT in CRC. Using immunohis- tochemistry, we showed that GREM1-expressing stromal cells harbor prominent features of myofibroblasts (i.e., cancer-associated fibroblasts), such as expression of Introduction α -smooth muscle actin and laminin-beta-1, and were in contextual proximity to invasion fronts with loss of the Bone morphogenetic proteins (BMPs) are a group of phylo- tight junction protein occludin and parallel nuclear accu- genetically conserved signaling molecules, which belong mulation of β -catenin, two prominent EMT hallmarks.
    [Show full text]
  • Rescue Screens with Secreted Proteins Reveal Compensatory Potential of Receptor Tyrosine Kinases in Driving Cancer Growth
    Author Manuscript Published OnlineFirst on August 8, 2012; DOI: 10.1158/2159-8290.CD-12-0237 Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. Secretomics rescue screens 1 Rescue screens with secreted proteins reveal compensatory potential of receptor tyrosine kinases in driving cancer growth Fred Harbinski1,8, Vanessa J. Craig2,8, Sneha Sanghavi1, Douglas Jeffery1, Lijuan Liu1, Kelly Ann Sheppard1, Sabrina Wagner2, Christelle Stamm2, Andreas Buness2, Christian Chatenay-Rivauday2, Yao Yao3, Feng He4, Chris X. Lu5, Vito Guagnano6, Thomas Metz7, Peter M. Finan1, Francesco Hofmann2, William R. Sellers8, Jeffrey A. Porter1, Vic E. Myer1, Diana Graus-Porta2, Christopher J. Wilson1, Alan Buckler1, and Ralph Tiedt2 Authors' Affiliations: 1Novartis Institutes for BioMedical Research, Developmental and Molecular Pathways, Cambridge, MA; 2Novartis Institutes for BioMedical Research, Disease Area Oncology, Basel, Switzerland; 3China Novartis Institutes for BioMedical Research, Oncology Translational Medicine, Shanghai, PR China; 4China Novartis Institutes for BioMedical Research, Global Discovery Chemistry, Shanghai, PR China; 5China Novartis Institutes for BioMedical Research, Developmental and Molecular Pathways, Shanghai, PR China; 6Novartis Institutes for BioMedical Research, Global Discovery Chemistry, Basel, Switzerland; 7Oncotest GmbH, Freiburg, Germany; 8Novartis Institutes for BioMedical Research, Disease Area Oncology, Cambridge, MA. Corresponding Authors: R. Tiedt, Novartis Institutes for BioMedical Research, Klybeckstrasse 141, 4057 Basel, Switzerland, Phone: 41-61-696-1981, e-mail: [email protected] 8These authors contributed equally to this work Downloaded from cancerdiscovery.aacrjournals.org on September 28, 2021. © 2012 American Association for Cancer Research. Author Manuscript Published OnlineFirst on August 8, 2012; DOI: 10.1158/2159-8290.CD-12-0237 Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited.
    [Show full text]
  • Role of Micrornas in Embryo Implantation Jingjie Liang, Shaoyu Wang and Zhengguang Wang*
    Liang et al. Reproductive Biology and Endocrinology (2017) 15:90 DOI 10.1186/s12958-017-0309-7 REVIEW Open Access Role of microRNAs in embryo implantation Jingjie Liang, Shaoyu Wang and Zhengguang Wang* Abstract Failure of embryo implantation is a major limiting factor in early pregnancy and assisted reproduction. Determinants of implantation include the embryo viability, the endometrial receptivity, and embryo-maternal interactions. Multiple molecules are involved in the regulation of implantation, but their specific regulatory mechanisms remain unclear. MicroRNA (miRNA), functioning as the transcriptional regulator of gene expression, has been widely reported to be involved in embryo implantation. Recent studies reveal that miRNAs not only act inside the cells, but also can be released by cells into the extracellular environment through multiple packaging forms, facilitating intercellular communication and providing indicative information associated with physiological and pathological conditions. The discovery of extracellular miRNAs shed new light on implantation studies. MiRNAs provide new mechanisms for embryo-maternal communication. Moreover, they may serve as non-invasive biomarkers for embryo selection and assessment of endometrial receptivity in assisted reproduction, which improves the accuracy of evaluation while reducing the mechanical damage to the tissue. In this review, we discuss the involvement of miRNAs in embryo implantation from several aspects, focusing on the role of extracellular miRNAs and their potential applications in assisted reproductive technologies (ART) to promote fertility efficiency. Keywords: Implantation, Viable embryo, Endometrial receptivity, MicroRNA, Extracellular vesicle Background rate has not been greatly improved, and challenges remain Embryo implantation is a crucial step of pregnancy regarding the poor accuracy of the methods to assess em- establishment in mammals and occurs in a restricted bryonic viability and endometrial receptivity.
    [Show full text]